March 30, 2020
Vicore submits clinical trial application for phase II trial with C21 in IPF 2020-03-30
Media
March 27, 2020
Nordic Nanovector ASA publishes 2019 Annual Report
March 26, 2020
Orexo publishes the Annual Report for 2019
March 26, 2020
Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study
March 26, 2020
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 25, 2020
Orexo has repurchased 14 percent of own corporate bonds
March 24, 2020
The Lancet Haematology Publishes Results from Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)
March 23, 2020
First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
March 23, 2020
Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical Officer
March 23, 2020
Dr. Matthias Friebe joins Camel-IDS as acting Chief Technology Officer